» Articles » PMID: 11958535

Uptake of Mannose-terminal Glucocerebrosidase in Cultured Human Cholinergic and Dopaminergic Neuron Cell Lines

Overview
Journal Neurochem Res
Specialties Chemistry
Neurology
Date 2002 Apr 18
PMID 11958535
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Enzyme replacement therapy has been shown to be particularly effective for patients with type 1 (non-neuronopathic) Gaucher disease. However, intravenously administered glucocerebrosidase does not reverse or halt the progression of brain damage in patients with type 2 (acute neuronopathic) Gaucher disease. A previous investigation revealed that intracerebral infusion of mannose-terminal glucocerebrosidase was safe in experimental animals. The enzyme had a comparatively long half-life in the brain. It was transported by convection from the site of infusion along white matter fiber tracts to the cerebral cortex where it was endocytosed by neurons. In anticipation of intracerebral administration of mannose-terminal glucocerebrosidase to patients with type 2 Gaucher disease, it was important to learn the mechanism involved in its cellular uptake. We therefore compared the endocytosis of this enzyme by J774 macrophage cells with that in two human neuronal cell lines and a human astrocyte cell line. Mannose-terminal glucocerebrosidase was taken up by cholinergic LA-N-2 cells, but to a much lower extent than by macrophages. Considerably less of the enzyme was endocytosed by dopaminergic SH-SY5Y cells. It was not taken up by NHA astrocytes. The findings provide encouragement for an exploration of intracerebral administration of glucocerebrosidase in patients with type 2 Gaucher disease.

Citing Articles

Deletion of Gba in neurons, but not microglia, causes neurodegeneration in a Gaucher mouse model.

Duffy H, Byrnes C, Zhu H, Tuymetova G, Lee Y, Platt F JCI Insight. 2024; 9(21).

PMID: 39312723 PMC: 11601582. DOI: 10.1172/jci.insight.179126.


GBA1 Variants and Parkinson's Disease: Paving the Way for Targeted Therapy.

Huh Y, Usnich T, Scherzer C, Klein C, Chung S J Mov Disord. 2023; 16(3):261-278.

PMID: 37302978 PMC: 10548077. DOI: 10.14802/jmd.23023.


Systemic enzyme delivery by blood-brain barrier-penetrating SapC-DOPS nanovesicles for treatment of neuronopathic Gaucher disease.

Sun Y, Liou B, Chu Z, Fannin V, Blackwood R, Peng Y EBioMedicine. 2020; 55:102735.

PMID: 32279952 PMC: 7251241. DOI: 10.1016/j.ebiom.2020.102735.


A peptide-linked recombinant glucocerebrosidase for targeted neuronal delivery: Design, production, and assessment.

Gramlich P, Westbroek W, Feldman R, Awad O, Mello N, Remington M J Biotechnol. 2016; 221:1-12.

PMID: 26795355 PMC: 5381155. DOI: 10.1016/j.jbiotec.2016.01.015.

References
1.
Neudorfer O, Giladi N, Elstein D, Abrahamov A, Turezkite T, AGHAI E . Occurrence of Parkinson's syndrome in type I Gaucher disease. QJM. 1996; 89(9):691-4. DOI: 10.1093/qjmed/89.9.691. View

2.
Schiffmann R, Heyes M, Aerts J, Dambrosia J, Patterson M, DeGraba T . Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann Neurol. 1997; 42(4):613-21. DOI: 10.1002/ana.410420412. View

3.
Yamaguchi Y, Hardison W . Hepatocyte horseradish peroxidase uptake is saturable and inhibited by mannose-terminal glycoproteins. Am J Physiol. 1993; 264(5 Pt 1):G880-5. DOI: 10.1152/ajpgi.1993.264.5.G880. View

4.
Schluff P, Flott-Rahmel B, Gieselmann V, Zimmer P, Das A, Ullrich K . Localization of receptors for endocytosis of lysosomal enzymes on different brain cells. J Inherit Metab Dis. 1998; 21(3):313-7. DOI: 10.1023/a:1005305213832. View

5.
Seeger R, Rayner S, Banerjee A, Chung H, Laug W, NEUSTEIN H . Morphology, growth, chromosomal pattern and fibrinolytic activity of two new human neuroblastoma cell lines. Cancer Res. 1977; 37(5):1364-71. View